Among patients with T2DM, 22 were on metformin, 6 on glucagon-like-peptide-1 agonists, 5 on gliflozins, 5 on insulin, and 1 on dipeptidyl-peptidase-4-inhibitors. This evidence concerns the gene INS and type 2 diabetes mellitus.